Introduction Biosimilar monoclonal antibodies (mAbs) are biologic drugs designed to be highly similar to already approved reference monoclonal ...
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) ...
Despite missing its primary endpoint, Equillium is pushing ahead with itolizumab citing its complete response by day 99.
Dr. Jianjun ZOU, General Manager and CEO of Junshi Biosciences, said, "Toripalimab's approval in Singapore represents our ...
SUZHOU, China, March 27, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today reported 2024 annual ...
DelveInsight’s, “Chronic Kidney Disease Pipeline Insight 2025” report provides comprehensive insights about 75+ companies and ...
News-Medical.Net on MSN15h
Fusion proteins enable the creation of monoclonal antibodiesThe Food and Drug Administration has approved more than 100 monoclonal antibodies to treat a range of diseases. Other antibodies are used by physicians to diagnose conditions or by scientists to ...
Predictive biomarkers of immunotherapy response are critical for clinical practice. In this study, baseline plasma sCD27 was ...
“Automation has already been heavily utilized in many aspects of mAb manufacturing, such as process control, monitoring, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback